Fierce Pharma
JANUARY 3, 2024
As the J.P. | As the J.P. Morgan Healthcare Conference rolled on in San Francisco, BioNTech, Alnylam and many other companies updated investors on their strategies heading into 2024.
MedCity News
JANUARY 3, 2024
Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm.
Fierce Pharma
JANUARY 3, 2024
Gene therapies have been approved for certain patients with beta thalassemia. After a successful phase 3 readout, Agios hopes it can reach a unique subgroup and eventually all patients. | Gene therapies have been approved for certain patients with beta thalassemia. After a successful phase 3 readout, Agios hopes it can reach a unique subgroup and eventually all patients.
MedCity News
JANUARY 3, 2024
Aetna Better Health of Kentucky, Avēsis and MapHabit have teamed up to support 200 Kentucky children with autism or intellectual disabilities. The pilot program will help the patients with activities of daily living, such as oral hygiene.
Speaker: Kevin Burke
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
Fierce Pharma
JANUARY 3, 2024
As the J.P. Morgan Healthcare Conference moves into its third day, we're covering the latest developments here. | On Wednesday at the the J.P. Morgan Healthcare Conference, attendees will get a chance to hear from AbbVie, Amarin and several other pharmaceutical companies.
pharmaphorum
JANUARY 3, 2024
The UK medicines regulator has launched its mutual recognition framework for authorising medicines in a move that it says will help to bring new drugs to patients in the UK more quickly.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
JANUARY 3, 2024
By leveraging analytics to optimize the patient experience in clinical trials, patient attrition will decrease, improving clinical outcomes and research goals.
Fierce Pharma
JANUARY 3, 2024
As the J.P. Morgan Healthcare Conference kicked off in San Francisco, EY released its annual report on the industry's dealmaking firepower. | As the J.P. Morgan Healthcare Conference kicked off in San Francisco, EY released its annual report on the industry's dealmaking firepower. Plus, Moderna, bluebird and other companies updated investors on their businesses heading into 2024.
MedCity News
JANUARY 3, 2024
The evolution of ECMO from a last-resort intervention to a mainstay of modern critical care is a testament to the relentless pursuit of better patient outcomes in the field of medicine. Unfortunately, despite the immense life-saving capability of this therapy, it remains vastly underutilized.
Fierce Pharma
JANUARY 3, 2024
When GSK laid out $90 million upfront to acquire rights to Scynexis’ antifungal Brexafemme last spring, the British pharma threw a lifeline to a company whose blockbuster launch ambitions had hit t | GSK has downgraded a licensing deal for Scynexis' antifungal ibrexafungerp following an ongoing recall of the drug's approved form, Brexafemme.
Advertiser: ZoomInfo
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
Pharmaceutical Technology
JANUARY 3, 2024
A new report from Novotech delves into the multifaceted landscape of HIV, focusing on its impact, treatment, and global initiatives.
Fierce Pharma
JANUARY 3, 2024
After a dispute over milestone payments derailed a 2019 heart med collaboration, Daiichi Sankyo and Esperion Therapeutics have mended fences with a $125 million settlement. | The agreement amends terms of the companies' 2019 partnership on heart med Nexletol and dismisses Esperion's lawsuit over milestone payments ahead of a potential European label expansion.
MedCity News
JANUARY 3, 2024
Medical device startup CardioMech raised $13 million to advance the development and validation of its flagship device, which is designed to treat degenerative mitral valve regurgitation. The catheter-based device seeks to offer an uncomplicated, direct procedure for patients eligible for open-heart surgery as well as those considered eligible for the surgery.
Fierce Pharma
JANUARY 3, 2024
Welcome to 2024's regulatory tracker for Fierce Pharma. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
JANUARY 3, 2024
On New Year’s Day, two Missouri health systems — St. Louis-based BJC HealthCare and Kansas City-based St. Luke’s Health System — officially completed their merger. The combined health system comprises 28 hospitals and hundreds of clinics serving 6 million people, and it is expected to generate $10 billion in annual revenue.
European Pharmaceutical Review
JANUARY 3, 2024
Korserdu ® (elacestrant) is the first treatment indicated for ER+, HER2- advanced or metastatic breast cancer tumours with ESR1 mutations. The endocrine therapy has been granted a marketing authorisation by the UK Medicines & Healthcare products Regulatory Agency (MHRA). This represents the first endocrine therapy innovation in nearly 20 years. The small molecule treatment is authorised for postmenopausal women, and men, with oestrogen receptor (ER)-positive, HER2-negative, locally advanced
pharmaphorum
JANUARY 3, 2024
UK report calls for the mothballed Rosalind Franklin Lab to be repurposed as a manufacturing unit to support clinical trials of bacteriophages as new antimicrobial agents
European Pharmaceutical Review
JANUARY 3, 2024
Outsourcing has become a necessity for many pharmaceutical companies; even the outsourcing of regulatory functions has grown over the past several years and is expected to increase steadily in future. The pharmaceutical regulatory affairs outsourcing market is thus projected to rise from $7 billion in 2022 to $15 billion in 2032, 1 driven by the growing number of clinical trial applications (see Figure 1 ) 2 and product registrations.
Advertiser: ZoomInfo
In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.
PharmaTimes
JANUARY 3, 2024
NaviCam ProScan is the first AI-assisted reading tool for gastrointestinal bleeding
Pharmaceutical Technology
JANUARY 3, 2024
Novartis will pay Voyager $100m upfront and up to $1.2bn in milestone-based payments and royalties on net sales.
PharmaTimes
JANUARY 3, 2024
The new hub will be located in the King’s Cross Knowledge Quarter, London
European Pharmaceutical Review
JANUARY 3, 2024
Boehringer Ingelheim has agreed to collaborate with Suzhou Ribo Life Science Co and Ribocure Pharmaceuticals AB (Ribo), to develop new RNAi therapeutics for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The deal exceeds a value of $2 billion and will utilise Ribo’s expertise in small interfering RNA (siRNA) treatments.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
JANUARY 3, 2024
This collaboration comes six years after the German company Boehringer signed two agreements to develop treatments for NASH.
European Pharmaceutical Review
JANUARY 3, 2024
What are the top trends relating to sterility testing of ATMPs? For me, one of the most promising developments involves the use of the next-generation sequencing-based sterility test (NGSST), which uses whole genome amplification and sequencing followed by microorganism identification with 48 hours. 1 This method removes the requirements for a culture period and has a higher accuracy than other rapid testing methods such as ATP bioluminescence.
Pharmacy Times
JANUARY 3, 2024
However, comprehensive policy and payment structures are needed to ensure care sustainability.
Pharmaceutical Technology
JANUARY 3, 2024
The first of a two-part series on therapies that receive an FDA priority review designation dives into how these vouchers incentivise innovation for low-commercial value-diseases.
Advertiser: ZoomInfo
As prospects define their problem, search for solutions, and even change jobs, they are generating high-value signals that the best go-to-market teams can leverage to close more deals. This is where signal-based selling comes into play. ZoomInfo CEO Henry Schuck recently broke down specific ways to put four key buying signals into action with the experts from 30 Minutes to President’s Club.
Pharmacy Times
JANUARY 3, 2024
Liraglutide, a glucagon-like peptide 1 receptor agonist, has shown a clinically and significant reduction in glycated hemoglobin for those with type 2 diabetes.
PharmExec
JANUARY 3, 2024
VYD222 is a broadly neutralizing, half-life extended monoclonal antibody developed specifically to prevent COVID-19 in immunocompromised adults and adolescents.
Contrarian Sales Techniques
JANUARY 3, 2024
Navigating through a week in the sales world is like embarking on a mini-adventure, each day bringing its own set of challenges and triumphs. Let's break down the weekly routine of a sales superstar into beginning, middle, and end segments. This isn't just about getting through the week. It's about maximizing each day to its fullest potential. So, let's turn the pages of this weekly planner together.
PharmExec
JANUARY 3, 2024
JAMA study evaluates the ability of artificial intelligence to transform electronic health.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Expert insights. Personalized for you.
276 
Let's personalize your content